BridgeBio Oncology Therapeutics, Inc Stock Price, News & Analysis

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) said its leadership will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 5:15 p.m. PT. A live webcast will be available on the company’s Events page and a replay will remain accessible for at least 90 days after the presentation.

This provides investors a scheduled opportunity for management commentary on clinical programs and strategy.

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced an inducement grant awarded December 10, 2025 under BBOT’s 2025 Inducement Plan for an individual hired in November 2025.

The award comprises non-qualified stock options to purchase 53,060 shares at an exercise price of $12.88 per share (the Nasdaq closing price on the grant date). Options vest 25% after one year and the remainder in 36 equal monthly installments, subject to continued service.

The 2025 Inducement Plan was adopted by the board in October 2025 and the compensation committee (all independent directors) approved the Awards as a material inducement under Nasdaq Listing Rule 5635(c)(4).

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced late-breaking preclinical data on BBO-10203 at SABCS on Dec 10, 2025. Data show BBO-10203 is a first-in-class covalent RAS:PI3Kα breaker that binds PI3Kα at Cys242, blocks RAS-driven PI3Kα-AKT signaling, and produces dose- and time-dependent pAKT inhibition after oral dosing without inducing hyperglycemia in glucose tolerance testing.

BBO-10203 demonstrated robust anti-tumor activity as monotherapy and combined with fulvestrant, ribociclib, trastuzumab or chemotherapy in preclinical breast cancer models. A Phase 1 trial (BREAKER-101; NCT06625775) is enrolling with initial Phase 1 data expected in first half of 2026.

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) said members of its leadership team will present at two investor healthcare conferences in early December 2025.

Presentation schedule: Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 2:00 PM ET, and Evercore 8th Annual Healthcare Conference on Wednesday, December 3, 2025 at 9:35 AM ET. Live webcasts will be available on the company's Events page, with replays accessible for at least 90 days after each event.

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) reported Q3 2025 results and corporate updates on Nov 12, 2025. The company closed a SPAC business combination in August and began trading as BBOT. As of Sept 30, 2025, BBOT held $468.3 million in cash, cash equivalents and marketable securities, which it expects will fund operations into 2028. BBOT advanced three internally discovered Phase 1 programs (BBO-8520, BBO-10203, BBO-11818) and expects initial clinical data readouts across the portfolio in 2026. BBO-8520 has FDA Fast Track designation for previously treated KRAS G12C metastatic NSCLC. Q3 operating metrics included R&D expenses of $35.1M, G&A expenses of $14.1M, and a net loss of $44.8M.

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced that its leadership team will present at the Jefferies Global Healthcare Conference on Monday, November 17, 2025 at 2:30 p.m. GMT. A live webcast will be available on the company’s Events page at https://investors.bbotx.com/news-events/events. A replay of the webcast will be accessible for at least 90 days after the event.

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced two poster presentations at the San Antonio Breast Cancer Symposium (SABCS), Dec 9-12, 2025, in San Antonio, Texas. Both posters feature BBO-10203, described as a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction.

Details: a Late-Breaking Pre-clinical poster (Abstract 3568, Presentation PS2-12-06) on Dec 10, 5:00–6:30 p.m. CT by Kerstin Sinkevicius, PhD, reports tumor growth inhibition alone and combined with fulvestrant or ribociclib without inducing hyperglycemia. A Trials-in-Progress poster (Abstract 203, Presentation PS5-07-06) on Dec 12, 12:30–2:00 p.m. CT by Andreas Varkaris, MD, PhD, outlines the phase 1a/1b BREAKER-101 study of BBO-10203 in advanced solid tumors.

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) reported preclinical data showing BBO-10203 selectively breaks the RAS:PI3Kα interaction, covalently binding PI3Kα at cysteine 242 and inhibiting RAS-driven PI3Kα-AKT signaling without inducing hyperglycemia or hyperinsulinemia in glucose tolerance testing.

In vivo studies showed oral bioavailability, complete target engagement at low nanomolar levels, robust monotherapy anti-tumor activity across KRAS-mutant CDX, PDX and GEM models, and deep tumor regressions when combined with BBOT’s KRAS inhibitors BBO-8520 and BBO-11818 at well-tolerated doses. Phase 1 BREAKER-101 is enrolling; initial Phase 1 clinical data expected in H1 2026.

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) presented preclinical data on BBO-11818 at the 2025 AACR‑NCI‑EORTC conference showing potent pan‑KRAS activity in KRASG12D and KRASG12V models.

Key findings: single‑digit nanomolar EC50s for ERK inhibition and proliferation in KRAS mutant cell lines; >1000‑fold lower potency versus NRAS, HRAS, and BRAF‑mutant lines; oral bioavailability and favorable PK with dose‑dependent pERK inhibition in vivo; tumor regressions in multiple CDX models; combination benefits with BBO‑10203, cetuximab, and anti‑PD‑1 including complete regressions in a KRASG12D syngeneic model. Phase 1 KONQUER‑101 is ongoing with initial clinical data expected in H2 2026.